JPWO2019087620A1 - Laser-printed supports, laser-printed patches and their manufacturing methods - Google Patents
Laser-printed supports, laser-printed patches and their manufacturing methods Download PDFInfo
- Publication number
- JPWO2019087620A1 JPWO2019087620A1 JP2019549957A JP2019549957A JPWO2019087620A1 JP WO2019087620 A1 JPWO2019087620 A1 JP WO2019087620A1 JP 2019549957 A JP2019549957 A JP 2019549957A JP 2019549957 A JP2019549957 A JP 2019549957A JP WO2019087620 A1 JPWO2019087620 A1 JP WO2019087620A1
- Authority
- JP
- Japan
- Prior art keywords
- support
- laser
- printed
- discoloration
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 238000002845 discoloration Methods 0.000 claims abstract description 48
- 239000000835 fiber Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000010410 layer Substances 0.000 claims abstract description 15
- 239000012790 adhesive layer Substances 0.000 claims abstract description 9
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 20
- 230000001678 irradiating effect Effects 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 7
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 15
- 238000007639 printing Methods 0.000 description 13
- -1 wool and silk Substances 0.000 description 12
- 229920000728 polyester Polymers 0.000 description 7
- 238000007648 laser printing Methods 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 229920001169 thermoplastic Polymers 0.000 description 4
- 239000004416 thermosoftening plastic Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FXTXRXXCMFFRTL-UHFFFAOYSA-N 4-ethyl-2-methylideneoctanoic acid Chemical compound CCCCC(CC)CC(=C)C(O)=O FXTXRXXCMFFRTL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000010330 laser marking Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002557 mineral fiber Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
インク等が薬物含有層に滲み出す恐れがなく、また、インク等の溶解による文字等の判読不能となることを回避することができ、さらにその表面に識別しやすい文字等が印刷されてなるレーザー印刷された支持体及び貼付剤ならびに簡便かつ容易にレーザー印刷された貼付剤を製造し得る、レーザー印刷された支持体又は貼付剤の製造方法を提供することを目的とする。変色誘起酸化物を含み、繊維により構成される支持体1であって、支持体1はその表面の一部が、前記変色誘起酸化物により変色しているレーザー印刷された支持体、及び変色誘起酸化物を含み、繊維により構成される支持体1、支持体1の一面に配置された粘着剤層、該粘着剤層の一面を被覆する剥離ライナーが積層されてなり、支持体1の表面の一部が、前記変色誘起酸化物により変色しているレーザー印刷された貼付剤。There is no risk of ink or the like seeping into the drug-containing layer, it is possible to prevent the characters or the like from becoming unreadable due to the dissolution of the ink or the like, and the laser is printed with easily identifiable characters or the like on its surface. It is an object of the present invention to provide a method for producing a laser-printed support or a patch, which can easily and easily produce a printed support and a patch and a laser-printed patch. A support 1 containing a discoloration-induced oxide and composed of fibers, the support 1 is a laser-printed support in which a part of the surface thereof is discolored by the discoloration-induced oxide, and a discoloration-induced support. A support 1 containing an oxide and composed of fibers, an adhesive layer arranged on one surface of the support 1, and a release liner covering one surface of the adhesive layer are laminated to form a surface of the support 1. A laser-printed patch that is partially discolored by the discoloration-induced oxide.
Description
本発明は、レーザー印刷された支持体、レーザー印刷された貼付剤及びそれらの製造方法に関する。 The present invention relates to a laser-printed support, a laser-printed patch, and a method for producing them.
従来から、貼付剤として、テープ剤、パップ剤等が汎用されている。これらの貼付剤は、その形態が殆ど同一であり、外形、色彩も互いに近似することから、一旦包装袋から取り出された後は、この貼付剤に含まれる成分等を判別することが困難である。また、種々の規制によって、包装袋から取り出した貼付剤の薬物名が認識できる表示が求められることもある。
これに対して、支持体である不織布にエンボス加工を施す方法(例えば、特許文献1)、支持体にレーザー照射により直接印字する方法(例えば、特許文献2)等が提案されている。また、貼付剤の支持体である不織布に、直接文字をインク等で印刷し、識別する方法が考えられる。Conventionally, tape agents, poultices and the like have been widely used as patches. Since these patches have almost the same form and their outer shapes and colors are similar to each other, it is difficult to distinguish the components contained in the patches once they are taken out from the packaging bag. .. In addition, various regulations may require that the drug name of the patch taken out from the packaging bag be recognizable.
On the other hand, a method of embossing a non-woven fabric as a support (for example, Patent Document 1), a method of directly printing on a support by laser irradiation (for example, Patent Document 2), and the like have been proposed. Further, a method of directly printing characters on the non-woven fabric which is the support of the patch with ink or the like and identifying them can be considered.
しかし、エンボス加工やレーザー印字は、識別しにくく、識別を容易にするために大きなエネルギーが負荷されることとなり、支持体の変質を招き、薬剤に対する影響が懸念される。また、インクによる印刷ではインクが薬物含有層に滲み出す恐れがあり、また、インクの溶解により文字等の判読ができなくなるという問題があった。 However, embossing and laser printing are difficult to identify, and a large amount of energy is applied to facilitate the identification, which causes deterioration of the support and is concerned about the influence on the drug. Further, in printing with ink, there is a problem that the ink may seep into the drug-containing layer, and the characters and the like cannot be read due to the dissolution of the ink.
本発明は、上記課題に鑑みてなされたものであり、支持体を変質させず、インク等が薬物含有層に滲み出す恐れがなく、また、インク等の溶解による文字等の判読不能となることを回避することができ、さらにその表面に識別しやすい文字等が印刷されてなるレーザー印刷された支持体及び貼付剤ならびに簡便かつ容易にレーザー印刷された貼付剤を製造し得る、レーザー印刷された支持体又は貼付剤の製造方法を提供することを目的とする。 The present invention has been made in view of the above problems, and the support is not altered, there is no risk of ink or the like oozing out into the drug-containing layer, and characters or the like become unreadable due to dissolution of the ink or the like. Laser-printed, which can easily and easily produce a laser-printed support and a patch on which easily identifiable characters and the like are printed on the surface thereof, and a laser-printed patch. It is an object of the present invention to provide a method for producing a support or a patch.
本願は以下の発明を含む。
(1)変色誘起酸化物を含み、繊維により構成された支持体であって、
該支持体は、表面の一部が、前記変色誘起酸化物により変色していることを特徴とするレーザー印刷された支持体。
(2)前記変色誘起酸化物が、前記支持体中に均一に含有されている上記に記載のレーザー印刷された支持体。
(3)前記変色誘起酸化物が、酸化チタンである上記に記載のレーザー印刷された支持体。
(4)変色誘起酸化物を含み、繊維により構成された支持体、
該支持体の一面に配置された粘着剤層、
該粘着剤層の一面を被覆する剥離ライナーが積層されてなり、
前記支持体は、表面の一部が、前記変色誘起酸化物により変色していることを特徴とするレーザー印刷された貼付剤。
(5)前記粘着剤層に、薬物が含有されている上記に記載のレーザー印刷された貼付剤。
(6)変色誘起酸化物を含み、繊維により構成された支持体にレーザー光を照射して、前記支持体の表面の一部を、前記変色誘起酸化物により変色させることを含むレーザー印刷された支持体又は貼付剤の製造方法。The present application includes the following inventions.
(1) A support containing a discoloration-induced oxide and composed of fibers.
The support is a laser-printed support characterized in that a part of the surface is discolored by the discoloration-induced oxide.
(2) The laser-printed support according to the above, wherein the discoloration-induced oxide is uniformly contained in the support.
(3) The laser-printed support according to the above, wherein the discoloration-induced oxide is titanium oxide.
(4) A support containing a discoloration-induced oxide and composed of fibers.
An adhesive layer arranged on one surface of the support,
A release liner covering one surface of the pressure-sensitive adhesive layer is laminated.
The support is a laser-printed patch characterized in that a part of the surface thereof is discolored by the discoloration-induced oxide.
(5) The laser-printed patch according to the above, wherein a drug is contained in the pressure-sensitive adhesive layer.
(6) Laser printing including irradiating a support containing a discoloration-induced oxide and composed of fibers with laser light to discolor a part of the surface of the support with the discoloration-induced oxide. A method for manufacturing a support or a patch.
本願のレーザー印刷された支持体及び貼付剤は、支持体を変質させず、インク等が薬物含有層に滲み出す恐れがなく、また、インク等の溶解による文字等の判読不能となることを回避することができ、その表面に識別しやすい文字等の印刷を維持することができる。
また、本願のレーザー印刷された支持体又は貼付剤の製造方法によれば、簡便かつ容易にレーザー印刷によって、識別しやすい文字等の印刷された貼付剤を製造することができる。The laser-printed support and patch of the present application do not deteriorate the support, there is no risk of ink or the like seeping into the drug-containing layer, and the characters or the like become unreadable due to the dissolution of the ink or the like. It is possible to maintain the printing of easily identifiable characters and the like on the surface thereof.
Further, according to the method for producing a laser-printed support or patch of the present application, it is possible to easily and easily manufacture a patch with printed characters or the like that can be easily identified by laser printing.
〔レーザー印刷された支持体〕
本願におけるレーザー印刷された支持体は、その表面の一部が、変色誘起酸化物により変色することによって、任意の文字、形状等が適所に配置されている。これによって、インクを用いた印刷等によって生じる文字等のにじみを回避することができ、細かい又は小さい字、線、図形などを鮮明に表示することができる。また、インクは通常有機物質を含有することから、高温に対して劣化する等により、色落ち等が生じることがあるが、レーザー印刷では、高温による変色又は色落ちを回避することができる。さらに、支持体自体の構成材料が劣化するような印字形態を採用しないために支持体の劣化、変質を回避することができ、支持体の表面形態を、印刷前後で維持することができる。[Laser-printed support]
In the laser-printed support of the present application, a part of the surface thereof is discolored by the discoloration-induced oxide, so that arbitrary characters, shapes, etc. are arranged in appropriate places. As a result, bleeding of characters and the like caused by printing with ink can be avoided, and fine or small characters, lines, figures and the like can be clearly displayed. Further, since the ink usually contains an organic substance, discoloration or the like may occur due to deterioration with respect to a high temperature or the like, but in laser printing, discoloration or discoloration due to a high temperature can be avoided. Further, since the printing form in which the constituent material of the support itself is deteriorated is not adopted, the deterioration and deterioration of the support can be avoided, and the surface form of the support can be maintained before and after printing.
本願のレーザー印刷された支持体は、当該分野において貼付剤の支持体として用いられるものであればよく、繊維を含んでいればよい。支持体の形態は、織布、編布又は不織布、これらの組み合わせ又は積層体等の種々のものが挙げられる。また、支持体には、高分子フィルム等が含まれていてもよい。この場合、高分子フィルムは少なくとも一面が織布、編布又は不織布で被覆されているものが好ましい。なかでも、支持体は、伸縮性を有するものが好ましく、一方向又は二方向への伸縮性を有する編布が好ましい。 The laser-printed support of the present application may be any one used as a support for a patch in the art, and may contain fibers. The form of the support includes various forms such as a woven fabric, a knitted fabric or a non-woven fabric, a combination thereof, or a laminated body. Further, the support may include a polymer film or the like. In this case, the polymer film preferably has at least one surface covered with a woven fabric, a knitted fabric, or a non-woven fabric. Among them, the support preferably has elasticity, and a knitted fabric having elasticity in one or two directions is preferable.
支持体の繊維素材は、例えば、天然繊維単独、熱可塑性繊維単独、非熱可塑性繊維単独、これらの2以上の混紡であってもよい。
天然繊維としては、木綿、麻等の植物繊維、羊毛、絹等の動物繊維、石綿等の鉱物繊維等が挙げられる。
熱可塑性繊維としては、ポリウレタン、ポリエステル、ポリプロピレン、アクリル、ナイロンなど熱可塑性樹脂からなる素材、例えば、ポリエステル繊維、ポリエチレン繊維、ポリプロピレン繊維、ポリアミド繊維、ポリ塩化ビニル繊維等が挙げられる。
非熱可塑性繊維としては、レーヨン、キュプラ等が挙げることができる。
これらの繊維を用いた不織布は、ウォータージェット、ニードルパンチ法等の公知の方法により製造することができる。
具合的には、ポリエステル繊維、ポリエチレン繊維、ポリプロピレン繊維、ポリアミド繊維、レーヨン繊維等が70%以上からなる、均一な厚みの編布状のものが好ましい。The fiber material of the support may be, for example, a natural fiber alone, a thermoplastic fiber alone, a non-thermoplastic fiber alone, or a blend of two or more of these.
Examples of natural fibers include plant fibers such as cotton and hemp, animal fibers such as wool and silk, and mineral fibers such as asbestos.
Examples of the thermoplastic fiber include materials made of a thermoplastic resin such as polyurethane, polyester, polypropylene, acrylic and nylon, for example, polyester fiber, polyethylene fiber, polypropylene fiber, polyamide fiber and polyvinyl chloride fiber.
Examples of the non-thermoplastic fiber include rayon and cupra.
Nonwoven fabrics using these fibers can be produced by known methods such as a water jet and a needle punching method.
In terms of condition, a knitted fabric having a uniform thickness containing 70% or more of polyester fiber, polyethylene fiber, polypropylene fiber, polyamide fiber, rayon fiber and the like is preferable.
このような支持体は、通常、外用貼付剤の支持体として使用されるものであり、その厚みは、例えば、0.1mm〜3mmが挙げられ、0.2mm〜2mmが好ましく、400〜800μmがより好ましい。 Such a support is usually used as a support for an external patch, and the thickness thereof is, for example, 0.1 mm to 3 mm, preferably 0.2 mm to 2 mm, preferably 400 to 800 μm. More preferred.
支持体に含有される変色誘起酸化物は、レーザー光の照射を受けることにより変色を誘起する酸化物を意味する。変色誘起酸化物は、酸化チタン、黄色三二酸化鉄及び三二酸化鉄等からなる群より選択される1種以上の酸化物が挙げられる。なかでも、酸化チタンが好ましい。 The discoloration-induced oxide contained in the support means an oxide that induces discoloration by being irradiated with laser light. Examples of the discoloration-induced oxide include one or more oxides selected from the group consisting of titanium oxide, yellow iron sesquioxide, iron sesquioxide and the like. Of these, titanium oxide is preferable.
変色誘起酸化物は、この変色誘起酸化物の変色前においては、支持体中に、つまり、面内及び厚み方向において、均一に含有されていることが好ましい。このような含有により、任意の文字、形状等を適所に配置するように変色させることができる。 It is preferable that the discoloration-induced oxide is uniformly contained in the support, that is, in the plane and in the thickness direction before the discoloration-induced oxide is discolored. With such inclusion, it is possible to discolor arbitrary characters, shapes, etc. so as to be arranged in an appropriate place.
変色誘起酸化物を支持体中に均一に含有させるために、例えば、支持体を準備した後、変色誘起酸化物を含む溶液又は分散液等に支持体を浸漬する方法、支持体を構成する繊維を準備する際に、変色誘起酸化物を含む溶液又は分散液等に繊維を浸漬、塗布、噴霧等する方法、支持体を構成する繊維材料を溶融又は溶解させ、その溶融物又は溶解液に変色誘起酸化物を添加して均一に混合する方法などが挙げられる。
このような支持体中への均一性及び取り扱い性を考慮して、変色有機酸化物は、例えば、粒状又は粉末状のものが好ましい。In order to uniformly contain the discoloration-induced oxide in the support, for example, a method of immersing the support in a solution or a dispersion containing the discoloration-induced oxide after preparing the support, fibers constituting the support. A method of immersing, coating, or spraying fibers in a solution or dispersion containing a discoloration-induced oxide, melting or dissolving the fiber material constituting the support, and discoloring the melt or solution. Examples thereof include a method in which an induced oxide is added and uniformly mixed.
In consideration of uniformity in such a support and handleability, the discolored organic oxide is preferably, for example, granular or powdery.
変色誘起酸化物は、例えば、支持体を構成する全繊維100質量部に対して、0.05質量部〜30質量部(0.05体積%〜30体積%)の割合で用いることができ、0.1質量部〜10質量部(0.1体積%〜10体積%)が好ましく、0.2質量部〜5質量部(0.2体積%〜5体積%)がより好ましくい。あるいは、別の観点から、変色誘起酸化物は、支持体への目付量として1g/m2〜200g/m2とすることができ、5g/m2〜150g/m2とすることが好ましい。The discoloration-induced oxide can be used, for example, at a ratio of 0.05 parts by mass to 30 parts by mass (0.05% by mass to 30% by mass) with respect to 100 parts by mass of all fibers constituting the support. 0.1 part by mass to 10 parts by mass (0.1% by mass to 10% by mass) is preferable, and 0.2 parts by mass to 5 parts by mass (0.2% by mass to 5% by mass) is more preferable. Alternatively, from another perspective, discoloration induced oxide may be a 1g / m 2 ~200g / m 2 as a weight per unit area of the support is preferably set to 5g / m 2 ~150g / m 2 .
支持体において、変色誘起酸化物を変色させ、任意の文字、形状等を適所に配置するために、変色誘起酸化物に対して、レーザー光を照射する方法が挙げられる。
ここでのレーザー光の種類、波長、出力等は、意図する変色を誘起するために適宜調整することができる。例えば、レーザー光は、紫外線レーザー光であることが好ましく、その光源としては、ArF(波長193nm)、KrCl(波長222nm)、KrF(波長248nm)、XeCl(波長308nm)、XeF(波長350nm)等の近紫外域から遠紫外域の光子エネルギーを有するエキシマレーザーが挙げられ、銅蒸気レーザー、YAGレーザー等の高調波のものであってもよい。In order to discolor the discoloration-induced oxide in the support and arrange arbitrary characters, shapes, etc. in appropriate places, a method of irradiating the discoloration-induced oxide with laser light can be mentioned.
The type, wavelength, output, etc. of the laser light here can be appropriately adjusted in order to induce the intended discoloration. For example, the laser light is preferably an ultraviolet laser light, and the light source thereof includes ArF (wavelength 193 nm), KrCl (wavelength 222 nm), KrF (wavelength 248 nm), XeCl (wavelength 308 nm), XeF (wavelength 350 nm) and the like. Examples thereof include an excima laser having photon energy in the near-ultraviolet region to the far-ultraviolet region, and may be a harmonic laser such as a copper steam laser or a YAG laser.
照射するレーザー光のエネルギーは、例えば、50mJ/cm2〜21000mJ/cm2、100mJ/cm2〜18000mJ/cm2が好ましい。300mJ/cm2〜10000mJ/cm2がより好ましい。このような範囲とすることにより、支持体等への熱的なダメージを回避することができる。なお、レーザー光の照射は、室温、それよりも低温又は高温下に、大気中、窒素ガス、真空下等のいずれの雰囲気中で行ってもよい。また、レーザー光の周波数は、例えば、10000Hz〜60000Hzが挙げられ、20000Hz〜30000Hzが好ましい。Energy of the irradiated laser light, for example, 50mJ / cm 2 ~21000mJ / cm 2, 100mJ / cm 2 ~18000mJ / cm 2 is preferred. 300mJ / cm 2 ~10000mJ / cm 2 is more preferable. By setting it in such a range, it is possible to avoid thermal damage to the support and the like. The laser light irradiation may be performed at room temperature, at a lower temperature or a higher temperature than that, in any atmosphere such as air, nitrogen gas, or vacuum. The frequency of the laser light is, for example, 10000 Hz to 60,000 Hz, preferably 20000 Hz to 30000 Hz.
レーザー光の支持体表面への照射は、直接照射する方法、レーザー光を透過するガラス板等を介して照射する方法、レンズを用いて集光又は拡大した光を照射する方法、レーザー光と支持体表面との間にマスクを介して全面にレーザー光を照射する方法等が挙げられる。通常、支持体に必要なマスキングを施した後、レーザー光を照射する方法、レーザー光のビーム径を絞り、レーザー走査により必要なマーキング個所にレーザー光を照射する方法が用いられる。 The surface of the support of the laser beam is irradiated directly, a method of irradiating through a glass plate or the like that transmits the laser beam, a method of irradiating a focused or magnified light using a lens, a laser beam and a support. Examples thereof include a method of irradiating the entire surface with a laser beam through a mask between the body surface and the body surface. Usually, a method of irradiating a laser beam after applying the necessary masking to the support, or a method of narrowing the beam diameter of the laser beam and irradiating the required marking portion by laser scanning is used.
変色誘起酸化物は、レーザー光の照射を受けた場合に、変色誘起酸化物中の酸素原子が脱離し、この酸素原子の脱離により、変色誘起酸化物中の酸素原子と非酸素原子との比率が変化し、目視で、その変色が認められる。例えば、酸化チタンの場合には、酸素原子とチタン原子との比率2:1が、レーザー光の照射により変化し、目視で、白色からグレーへの変色が認められる。なお、このような酸素原子の脱離は、支持体のレーザー光が照射される表面のみであることから、その表面下の支持体の厚み方向においては、変色誘起酸化物は、変色した部分以外の支持体中と同様の濃度で、均一に分散されている。このことは、後述するように、例えば、レーザー光の照射により変色した部分で、支持体を切断した場合の断面における目視又は顕微鏡による観察によって、確認することができる。 When the discoloration-induced oxide is irradiated with laser light, the oxygen atom in the discoloration-induced oxide is desorbed, and the desorption of the oxygen atom causes the oxygen atom and the non-oxygen atom in the discoloration-induced oxide to be desorbed. The ratio changes, and the discoloration is visually recognized. For example, in the case of titanium oxide, the ratio of oxygen atom to titanium atom 2: 1 changes by irradiation with laser light, and a discoloration from white to gray is visually observed. Since such desorption of oxygen atoms is performed only on the surface of the support irradiated with the laser beam, the discoloration-induced oxide is other than the discolored portion in the thickness direction of the support under the surface. It is uniformly dispersed at the same concentration as in the support of. As will be described later, this can be confirmed, for example, by visual inspection or microscopic observation of the cross section of the portion discolored by irradiation with laser light when the support is cut.
〔レーザー印刷された貼付剤〕
本願における貼付剤は、第十七改正日本薬局方による皮膚などに適用する製剤であり、主として、上述した支持体、粘着剤層、剥離ライナーがこの順に積層された、例えば、テープ剤及びパップ剤と称されるものを意味する。
上述した支持体を、貼付剤が備えることにより、インクを用いた印刷等に起因する薬物の汚染及び文字等の判読不能を回避することができる。また、支持体自体の構成材料が劣化するような印字形態を採用しないために、薬物の汚染が生じない。さらに、インクを用いない印刷に相当する文字等を、色誘起酸化物により変色により付与することができるために、装袋から取り出した貼付剤の薬物名等の認識を確実に行うことができる。[Laser-printed patch]
The patch in the present application is a preparation applied to the skin, etc. according to the 17th revised Japanese Pharmacopoeia, and mainly, the above-mentioned support, adhesive layer, and release liner are laminated in this order, for example, a tape agent and a poultice. Means what is called.
By providing the above-mentioned support with the patch, it is possible to avoid contamination of the drug and indecipherability of characters and the like due to printing using ink and the like. Further, since the printing form that deteriorates the constituent material of the support itself is not adopted, drug contamination does not occur. Further, since characters and the like corresponding to printing without using ink can be imparted by discoloration by the color-induced oxide, it is possible to surely recognize the drug name and the like of the patch taken out from the bag.
粘着剤層は、上述した支持体の変色していない表面に積層されており、通常、薬物を含有する。薬物としては、例えば、アセトアミノフェノン、フェナセチン、メフェナム酸、ジクロフェナクナトリウム、フルフェナム酸、アスピリン、サリチル酸ナトリウム、サリチル酸メチル、サリチル酸グリコール、アミノピリン、アルクロフェナク、イブプロフェン、ナプロキセン、フルルビプロフェン、ケトプロフェン、アンフェナクナトリウム、メピリゾール、インドメタシン、ピロキシカム、ロキソプロフェン、チアプロフェン、アセメタシン、フェルビナク、スリンダク、エトドラク、トルメチン、アンピロキシカム、アザプロパゾン、バルデコキシブ、ロフェコキシブ等の消炎鎮痛剤、ヒドロコルチゾン、トリアムシノロン、デキサメタゾン、プレドニゾロン等のステロイド系抗炎症剤、アミノ安息香酸エチル、リドカイン、塩酸リドカイン、塩酸テトラカイン、塩酸ブロカイン、塩酸ジブカイン、塩酸オキシブプロカイン、塩酸プロピトカイン等の局所麻酔剤、塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン、プロメタジン、塩酸シプロヘプタジン、塩酸ジフェニルピラリン等の抗ヒスタミン剤、サリチル酸、シクロピロクスオラミン、塩酸コロコナゾール等の寄生性皮膚疾患用剤、尿素等の皮膚軟化剤、カルシトリオール、塩酸チアミン、リン酸リボフラピンナトリウム、塩酸ピリドキシン、ニコチン酸アミド、パンテノール、アスコルビン酸等のビタミン剤等が挙げられる。 The pressure-sensitive adhesive layer is laminated on the non-discolored surface of the support described above and usually contains a drug. Drugs include, for example, acetaminophenone, phenacetin, mephenamic acid, diclofenac sodium, flufenamic acid, aspirin, sodium salicylate, methyl salicylate, glycol salicylate, aminopyrine, alcrophenac, ibprofen, naproxene, flurubiprofen, ketoprofen, amphenacone , Mepyrilol, indomethacin, pyroxicum, loxoprofen, thiaprofen, acemetacin, fervinac, slindac, etdrac, tolmethin, ampyroxicam, azapropazone, valdecoxib, lofecoxib and other anti-inflammatory analgesics, hydrocortisone, triamsinolone Local anesthetics such as ethyl aminobenzoate, lidocaine, lidocaine hydrochloride, tetracaine hydrochloride, brocaine hydrochloride, dibucaine hydrochloride, oxybuprocaine hydrochloride, propitocaine hydrochloride, diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, cipropheptazine hydrochloride, diphenylpyraline hydrochloride Anti-histamines such as, salicylic acid, cyclopyroxolamine, agents for parasitic skin diseases such as coroconazole hydrochloride, skin softeners such as urea, calcitriol, thiamine hydrochloride, sodium riboflamin phosphate, pyridoxin hydrochloride, nicotinic acid amide, bread Examples thereof include vitamin preparations such as tenol and ascorbic acid.
粘着剤としては、当該分野で公知のものであり、上述した薬物に影響を与えない成分により構成されていることが好ましい。例えば、ゴム系粘着剤、アクリル系粘着剤及び水溶性粘着剤等が挙げられる。 The pressure-sensitive adhesive is known in the art and is preferably composed of the above-mentioned components that do not affect the drug. For example, rubber-based pressure-sensitive adhesives, acrylic-based pressure-sensitive adhesives, water-soluble pressure-sensitive adhesives, and the like can be mentioned.
ゴム系粘着剤のゴム成分としては、天然ゴム、スチレン・ブタジエンゴム、スチレン−イソプレン−スチレンブロック共重合体、ブチルゴム等が挙げられる。
アクリル系粘着剤としては、アクリル酸・アクリル酸オクチルエステル共重合体、アクリル酸2−エチルヘキシル・ビニルピロリドン共重合体溶液、アクリル酸エステル・酢酸ビニルコポリマー等が挙げられる。
水溶性粘着剤としては、ゼラチン、ペクチン、アガロース、アルギン酸塩、キサンタンガム、デキストリン、メチルセルロース、エチルセルロース、ヒドロキシエチルセルロース、カルボキシメチルセルロース、ポリビニルアルコール、ポリビニルピロリドン、ポリエチレングリコール、無水マレイン酸共重合体、ポリアクリル酸及びその塩又はそれらの架橋体等の天然高分子、その変性物等が挙げられる。
これらの成分は、単独で又は2種以上を組み合わせて用いることができる。
粘着剤は、上述した成分以外に、当該分野で用いられる添加剤を含んでいてもよい。Examples of the rubber component of the rubber-based pressure-sensitive adhesive include natural rubber, styrene-butadiene rubber, styrene-isoprene-styrene block copolymer, and butyl rubber.
Examples of the acrylic pressure-sensitive adhesive include an acrylic acid / acrylic acid octyl ester copolymer, a 2-ethylhexyl acrylic acid / vinylpyrrolidone copolymer solution, and an acrylic acid ester / vinyl acetate copolymer.
Water-soluble pressure-sensitive adhesives include gelatin, pectin, agarose, alginate, xanthan gum, dextrin, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, maleic anhydride copolymer, polyacrylic acid and Examples thereof include natural polymers such as the salt or a crosslinked product thereof, and modified products thereof.
These components can be used alone or in combination of two or more.
The pressure-sensitive adhesive may contain additives used in the art in addition to the above-mentioned components.
薬物は、例えば、粘着剤を構成する全質量に対して、0.1質量%〜80質量%、好ましくは0.5〜10質量%で含有させることができる。
粘着剤層は、例えば、10μm〜3mmの厚みとすることができ、10μm〜1mmの厚みとすることが好ましく、30〜300μmの厚みとすることがより好ましい。The drug can be contained, for example, in an amount of 0.1% by mass to 80% by mass, preferably 0.5 to 10% by mass, based on the total mass constituting the pressure-sensitive adhesive.
The pressure-sensitive adhesive layer can have a thickness of, for example, 10 μm to 3 mm, preferably 10 μm to 1 mm, and more preferably 30 to 300 μm.
粘着剤層の支持体とは反対側の表面に、貼付剤の使用時まで粘着剤層の粘着面を保護するため、剥離ライナーが積層されている。剥離ライナーとしては、充分に軽い剥離性を確保できればよい。例えば、粘着剤層と接触する面にシリコーン樹脂、フッ素樹脂等を塗布することによって剥離処理が施された、ポリエステル、ポリ塩化ビニル、ポリ塩化ビニリデン、ポリエチレンテレフタレート等のフィルム、上質紙、グラシン紙等の紙、上質紙又はグラシン紙等とポリオレフィンとのラミネートフィルム等が挙げられる。 A release liner is laminated on the surface of the pressure-sensitive adhesive layer opposite to the support in order to protect the pressure-sensitive surface of the pressure-sensitive adhesive layer until the use of the patch. As the peeling liner, it suffices to ensure sufficiently light peelability. For example, films such as polyester, polyvinyl chloride, polyvinylidene chloride, polyethylene terephthalate, high-quality paper, glassin paper, etc., which have been peeled by applying silicone resin, fluororesin, etc. to the surface in contact with the adhesive layer. Examples thereof include a laminated film of polyolefin paper, high-quality paper, glassin paper, and the like.
〔レーザー印刷された支持体又は貼付剤の製造方法〕
レーザー印刷された支持体又は貼付剤の製造方法では、上述したように、変色誘起酸化物を含み、繊維からなる支持体を準備し、その支持体にレーザー光を照射して、支持体の表面の一部を、変色誘起酸化物により変色させることを含む。この変色により、任意の文字又は図形等を印刷することができる。
支持体へのレーザー光の照射は、上述したとおりであるが、特に、貼付剤を製造する場合、支持体を準備した後であれば、支持体に粘着剤層を形成する前後、剥離ライナー上に粘着剤層を形成したものを、支持体上に転写する前後等、任意のタイミングで、支持体にレーザー光の照射を行うことができる。
このような製造方法によって、簡便かつ自在に、さらに、薬物を支持体に適用した後においても、薬物を変質又は劣化させることなく、迅速に印刷することができる。[Manufacturing method of laser-printed support or patch]
In the method for producing a laser-printed support or patch, as described above, a support containing a discoloration-induced oxide and made of fibers is prepared, and the support is irradiated with laser light to irradiate the surface of the support with laser light. Including discoloring a part of the above with a discoloration-induced oxide. By this discoloration, any character or figure can be printed.
Irradiation of the support with laser light is as described above, but especially in the case of manufacturing a patch, after preparing the support, before and after forming the pressure-sensitive adhesive layer on the support, on the release liner. The support can be irradiated with laser light at any time, such as before and after transferring the adhesive layer formed on the support.
By such a manufacturing method, it is possible to print easily and freely, and even after applying the drug to the support, the drug can be printed quickly without deteriorating or deteriorating.
実施例1
ポリエステル製のニットを準備した。このニットは、通常、テープ剤に用いられるものであり、ニットの全質量に対して、0.3%の酸化チタンを含む。このニットは、ポリエステルの溶融液に酸化チタン粉末を混合、撹拌し、繊維状の紡糸したものによって形成されたものである。
準備したニットの一面に、UVレーザーマーキング装置(型式:LIS−250D(クオリカプス株式会社製))にて、パルスエネルギー48%、20kHzの条件でレーザー印刷した。Example 1
I prepared a polyester knit. This knit is usually used as a tape agent and contains 0.3% titanium oxide with respect to the total mass of the knit. This knit is formed by mixing and stirring titanium oxide powder with a polyester melt and spinning it into a fibrous form.
One side of the prepared knit was laser-printed with a UV laser marking device (model: LIS-250D (manufactured by Qualicaps Co., Ltd.)) under the conditions of pulse energy of 48% and 20 kHz.
実施例1の結果、図1に示すように、目視によって明確に判別することができるグレーの印字が認められた。そして、その印刷表面は、レーザー光の照射前から全く変質しておらず、凹凸、焼けなどが発生せず、平坦であった。
また、この印字された部分の支持体を切断し、その断面を目視で観察したところ、図2に示すように、支持体1表面からその厚み方向の1/2程度に、その表面と同様のグレーの変色部位2が認められ、支持体1の表面とは反対側の裏面側においては、その厚みの1/2程度に全く変色が認められなかった。As a result of Example 1, as shown in FIG. 1, gray printing that can be clearly discriminated by visual inspection was recognized. The printed surface was flat with no deterioration, no unevenness, no burning, etc., before the irradiation with the laser beam.
Further, when the support of the printed portion was cut and the cross section thereof was visually observed, as shown in FIG. 2, about 1/2 of the surface of the support 1 in the thickness direction was the same as the surface. A gray discolored portion 2 was observed, and no discoloration was observed at about 1/2 of the thickness on the back surface side opposite to the front surface of the support 1.
実施例2
レーザー印刷する時の条件として、描画の際に使用しているデザインデータ(CAD)の描画線数を実施例1の2倍とし、線と線との隙間を無くすこと以外は実施例1と同様の条件でレーザー印刷した。Example 2
As a condition for laser printing, the number of drawing lines of the design data (CAD) used for drawing is doubled as in Example 1, and the same as in Example 1 except that the gap between lines is eliminated. Laser printing was performed under the conditions of.
実施例2の結果、図3に示すように、目視によって明確に判別することができるグレーの印字が認められ、実施例1より濃い印字が得られた。 As a result of Example 2, as shown in FIG. 3, gray printing that can be clearly discriminated by visual inspection was recognized, and a darker printing than that of Example 1 was obtained.
実施例3
実施例1で用いたポリエステル製のニットを準備した。また、剥離ライナー上に塗厚厚みが100μmの粘着剤層を形成した。ニットの一面に、粘着剤層を貼り付け、貼付剤を形成した。
得られた貼付剤の粘着剤層が積層されていない面に、実施例1と同様にレーザー光を照射し、印字した。
その結果、実施例1と同様の結果が得られた。
なお、支持体に隣接する粘着剤層における薬物の変質は認められなかった。Example 3
The polyester knit used in Example 1 was prepared. Further, an adhesive layer having a coating thickness of 100 μm was formed on the release liner. An adhesive layer was attached to one surface of the knit to form an adhesive.
The surface of the obtained patch on which the pressure-sensitive adhesive layer was not laminated was irradiated with laser light in the same manner as in Example 1 to print.
As a result, the same result as in Example 1 was obtained.
No alteration of the drug was observed in the pressure-sensitive adhesive layer adjacent to the support.
1 支持体
2 変色部位1 Support 2 Discolored part
Claims (6)
該支持体は、表面の一部が、前記変色誘起酸化物により変色していることを特徴とするレーザー印刷された支持体。A support composed of fibers containing a discoloration-induced oxide.
The support is a laser-printed support characterized in that a part of the surface is discolored by the discoloration-induced oxide.
該支持体の一面に配置された粘着剤層、
該粘着剤層の一面を被覆する剥離ライナーが積層されてなり、
前記支持体は、表面の一部が、前記変色誘起酸化物により変色していることを特徴とするレーザー印刷された貼付剤。A support composed of fibers containing a tarnish-induced oxide,
An adhesive layer arranged on one surface of the support,
A release liner covering one surface of the pressure-sensitive adhesive layer is laminated.
The support is a laser-printed patch characterized in that a part of the surface thereof is discolored by the discoloration-induced oxide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017213172 | 2017-11-02 | ||
JP2017213172 | 2017-11-02 | ||
PCT/JP2018/035346 WO2019087620A1 (en) | 2017-11-02 | 2018-09-25 | Laser-printed backing, laser-printed patch, and methods for manufacturing same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019087620A1 true JPWO2019087620A1 (en) | 2020-09-24 |
JP7226326B2 JP7226326B2 (en) | 2023-02-21 |
Family
ID=66333050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019549957A Active JP7226326B2 (en) | 2017-11-02 | 2018-09-25 | LASER-PRINTED SUPPORT, LASER-PRINTED PAINT AND METHOD OF MANUFACTURING THEREOF |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7226326B2 (en) |
WO (1) | WO2019087620A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003102773A (en) * | 2001-09-28 | 2003-04-08 | Toko Yakuhin Kogyo Kk | Sticking material and lumbago band with printed letter |
WO2012121910A2 (en) * | 2011-03-04 | 2012-09-13 | 3M Innovative Properties Company | Laser marking process and articles |
JP2013503065A (en) * | 2009-08-31 | 2013-01-31 | スリーエム イノベイティブ プロパティズ カンパニー | Laser marking method and article |
-
2018
- 2018-09-25 JP JP2019549957A patent/JP7226326B2/en active Active
- 2018-09-25 WO PCT/JP2018/035346 patent/WO2019087620A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003102773A (en) * | 2001-09-28 | 2003-04-08 | Toko Yakuhin Kogyo Kk | Sticking material and lumbago band with printed letter |
JP2013503065A (en) * | 2009-08-31 | 2013-01-31 | スリーエム イノベイティブ プロパティズ カンパニー | Laser marking method and article |
WO2012121910A2 (en) * | 2011-03-04 | 2012-09-13 | 3M Innovative Properties Company | Laser marking process and articles |
US20130337213A1 (en) * | 2011-03-04 | 2013-12-19 | 3M Innovative Properties Company | Laser marking process and articles |
Also Published As
Publication number | Publication date |
---|---|
JP7226326B2 (en) | 2023-02-21 |
WO2019087620A1 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101030198B1 (en) | Adhesive preparation package | |
US8507081B2 (en) | Absorbing article with zones of different surface properties | |
RU2489141C2 (en) | Adhesion cover | |
US11759431B2 (en) | Abuse and misuse deterrent transdermal systems | |
ES2369053T3 (en) | ADHESIVE PATCH. | |
JP2015214550A (en) | Embossable and writable multilaminate backing construction | |
JP2015500329A5 (en) | ||
US9700522B2 (en) | Transdermal patch and method for delivery of vitamin B12 | |
AU2014239687A1 (en) | Transdermal drug delivery system containing rivastigmine | |
JP7226326B2 (en) | LASER-PRINTED SUPPORT, LASER-PRINTED PAINT AND METHOD OF MANUFACTURING THEREOF | |
JPWO2017164084A1 (en) | Patch preparation with anti-misuse properties | |
WO2020066188A1 (en) | Water-containing transdermal patch | |
JP2007151916A (en) | Adhesive skin patch | |
ITMI20120031A1 (en) | PACKAGING STRUCTURE FOR BIOMEDICAL FILMS | |
WO2006067514A1 (en) | Multilayered dosing systems | |
WO2020241685A1 (en) | Nanomesh multilayer body, method for producing conductive circuit and nanomesh bonding kit | |
WO2015055289A2 (en) | Packaging for non-touch application | |
US11903939B2 (en) | Patch preparations with accidental use prevention features | |
JP7281120B2 (en) | Patch and manufacturing method thereof | |
JP4374244B2 (en) | Patch | |
JP2010163398A (en) | Sheet patch | |
US20130165876A1 (en) | Patch preparation | |
WO2014171538A1 (en) | Substrate for transdermal patch and transdermal patch using same | |
JP2011148536A (en) | Plaster packaging structure | |
JP2003102773A (en) | Sticking material and lumbago band with printed letter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210811 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221006 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7226326 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |